Literature DB >> 20185495

New drugs for old: disinvestment and NICE.

Dyfrig A Hughes1, Robin E Ferner.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20185495     DOI: 10.1136/bmj.c572

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  19 in total

1.  From NCE to NICE: the role of pharmacoeconomics.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  [The crisis and medicines policy].

Authors:  Joan-Ramon Laporte; Montserrat Bosch
Journal:  Aten Primaria       Date:  2012-05-10       Impact factor: 1.137

Review 3.  Reorienting programme budgeting and marginal analysis (PBMA) towards disinvestment.

Authors:  Duncan Mortimer
Journal:  BMC Health Serv Res       Date:  2010-10-14       Impact factor: 2.655

4.  Generic and therapeutic substitutions in the UK: are they a good thing?

Authors:  Martin G Duerden; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

5.  Value-based pricing: incentive for innovation or zero net benefit?

Authors:  Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

6.  Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants.

Authors:  Ali A Alkhafaji; Ludovic Trinquart; Gabriel Baron; Moïse Desvarieux; Philippe Ravaud
Journal:  BMC Med       Date:  2012-11-20       Impact factor: 8.775

Review 7.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

8.  Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

Authors:  Nathalie Vernaz; Guy Haller; François Girardin; Benedikt Huttner; Christophe Combescure; Pierre Dayer; Daniel Muscionico; Jean-Luc Salomon; Pascal Bonnabry
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

Review 9.  Towards understanding the de-adoption of low-value clinical practices: a scoping review.

Authors:  Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox
Journal:  BMC Med       Date:  2015-10-06       Impact factor: 8.775

10.  Processes, contexts, and rationale for disinvestment: a protocol for a critical interpretive synthesis.

Authors:  Michael G Wilson; Moriah E Ellen; John N Lavis; Jeremy M Grimshaw; Kaelan A Moat; Joshua Shemer; Terry Sullivan; Sarah Garner; Ron Goeree; Roberto Grilli; Justin Peffer; Kevin Samra
Journal:  Syst Rev       Date:  2014-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.